eisai integrated report 2020

Learn more about Eisai today. Posted by ; On Maj 26, 2022; By using this site, you agree to our use of cookies. EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE SEVENTH TIMEHIGHEST RANKED GLOBAL PHARMACEUTICAL COMPANY, EISAI AIMS TO ADVANCE GASTROINTESTINAL CANCER TREATMENT WITH RESEARCH ACROSS MULTIPLE TUMOR TYPES AT ASCO GI 2023Highlights Include an Update from the Dose Escalation Part of a Phase 1 Study Evaluating the Novel Anticancer Agent, E7386, in Advanced Solid Tumors Including Colorectal CancerResearch from the LEAP (LEnvatinib And Pembrolizumab) Clinical Program May Provide New Information About Treating Patients with Unresectable Hepatocellular Carcinoma, EISAI FILES MARKETING AUTHORIZATION APPLICATION FOR ANTI-AMYLOID-BETA PROTOFIBRIL ANTIBODY LECANEMAB FOR EARLY ALZHEIMERS DISEASE IN JAPAN, EISAI LAUNCHES RENEWED SUSTAINABILITY PAGE, EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMERS DISEASE IN EUROPE, Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimers DiseaseSubmission for traditional approval follows FDA accelerated approval of LEQEMBI on the same day, and is based on data from the confirmatory Phase 3 Clarity AD clinical trial, Eisais Commitment to Scientific Evidence and Patient Safety, EISAIS APPROACH TO U.S. PRICING FOR LEQEMBI (LECANEMAB), A TREATMENT FOR EARLY ALZHEIMERS DISEASE, SETS FORTH OUR CONCEPT OF SOCIETAL VALUE OF MEDICINE IN RELATION TO PRICE OF MEDICINEMAXIMIZING VALUE FOR ALL STAKEHOLDERS WHILE GIVING BACK VALUE TO SOCIETY, FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimers DiseaseAccelerated Approval is based on Phase 2 data showing a reduction in amyloid-beta plaques in early AD patients treated with LEQEMBI Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials, YASUDA LOGISTICS AND EISAI ENTERS AGREEMENT TO TRANSFER EISAIS SUBSIDIARY EISAI DISTRIBUTION TO YASUDA LOGISTICS, ARTICLE REGARDING SAFETY INFORMATION OF LECANEMAB REPORTED BY SCIENCEINSIDER, EISAI INITIATES BLA SUBMISSION OF DATA FOR LECANEMAB IN CHINA, Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging, EISAI TO DIVEST RIGHTS FOR ANTI-EPILEPTIC DRUG FYCOMPA (perampanel) CIII IN UNITED STATES TO CATALYST PHARMACEUTICALS, EISAI TERMINATES SPONSORED AMERICAN DEPOSITARY RECEIPT PROGRAM, EISAI AND WASHINGTON UNIVERSITY SCHOOL OF MEDICINE IN ST. LOUIS ENTER INTO COMPREHENSIVE RESEARCH COLLABORATION AGREEMENT AIMING TO CREATE NEW THERAPIES FOR NEURODEGENERATIVE DISEASES, EISAI TO PRESENT PRECLINICAL AND CLINICAL RESEARCH ON ERIBULIN AT THE 2022 SAN ANTONIO BREAST CANCER SYMPOSIUM, EISAI PRESENTS FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMERS DISEASE AT CLINICAL TRIALS ON ALZHEIMERS DISEASE (CTAD) CONFERENCE, ELEVEN EXPERTS FROM LEADING MEDICAL INSTITUTIONS AND EIGHT EXPERTS FROM EISAI* PUBLISH FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMERS DISEASE IN THE NEW ENGLAND JOURNAL OF MEDICINE, (REVISION) ARTICLE REGARDING SAFETY INFORMATION OF LECANEMAB REPORTED BY SCIENCEINSIDER, EISAI ANNOUNCES APPROVAL OF PARTIAL CHANGE TO LABEL FOR DOSAGE AND ADMINISTRATION OF ARICEPT FOR TREATMENT OF DEMENTIA WITH LEWY BODIES, EISAI TO PRESENT LATEST DATA ON PERAMPANEL AT THE 76TH AMERICAN EPILEPSY SOCIETY (AES) ANNUAL MEETING, To Develop Japans First Blood Biomarker-Based Diagnostic Workflow for DementiaShimadzu, Eisai, Oita University, and Usuki City Medical Association Commence Joint Research, EISAI TO PRESENT FULL FINDINGS FROM LECANEMAB CONFIRMATORY PHASE 3 CLINICAL TRIAL (CLARITY AD) AND OTHER ALZHEIMERS DISEASE RESEARCH AT THE 15TH CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE, METOJECT SUBCUTANEOUS INJECTION SYRINGE (METHOTREXATE) LAUNCHED IN JAPAN FOR RHEUMATOID ARTHRITIS, EISAI TO DIVEST RIGHTS FOR MUSCLE RELAXANT MYONAL AND VERTIGO AND EQUILIBRIUM DISTURBANCE TREATMENT MERISLON IN ASIA TO DKSH, EISAI'S SALES SUBSIDIARY COLLABORATES WITH THAI LIFE INSURANCE TO SUPPORT ACCESS TO TREATMENTS FOR DEMENTIA, INCLUDING ALZHEIMERS DISEASE, IN THAILAND, EISAI SATISFIES ALL-CASE STUDY REQUIREMENT FOR ANTIEPILEPTIC AGENT INOVELON, EISAI ANNOUNCES PLANS TO SUBMIT APPLICATION FOR PARTIAL CHANGE TO LABEL FOR DOSAGE AND ADMINISTRATION OF ARICEPT FOR TREATMENT OF DEMENTIA WITH LEWY BODIES BASED ON RESULTS OF DRUG REEXAMINATION, EISAI COMPLETES CONSTRUCTION OF ITS NEW INJECTION/RESEARCH BUILDING AT KAWASHIMA INDUSTRIAL PARK IN JAPANTO STRENGTHEN ITS RESEARCH AND DEVELOPMENT FUNCTION FOR INJECTABLE DRUG FORMULATIONS, LECANEMAB CONFIRMATORY PHASE 3 CLARITY AD STUDY MET PRIMARY ENDPOINT, SHOWING HIGHLY STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN LARGE GLOBAL CLINICAL STUDY OF 1,795 PARTICIPANTS WITH EARLY ALZHEIMERS DISEASE, Notice of Purchase of Treasury Shares as a Result of the Processing of Fractional Shares Through Share Exchange(Purchase of Treasury Shares under Article 234, Paragraphs 4 and 5 and Article 416, Paragraph 4 of the Companies Act), METOJECT SUBCUTANEOUS INJECTION SYRINGE (METHOTREXATE) APPROVED IN JAPAN FOR RHEUMATOID ARTHRITIS, RELEASE OF DEMENTIA DISEASE AWARENESS VIDEOS FOR WORLD ALZHEIMERS DAY, SEPTEMBER 21LEARNING HELPS US TO BE KIND LIFE GOES ON: NO WAY ITS NOT HERE / TIMESLIP, Eisai and Merck & Co., Inc., Rahway, NJ, USA Present Results From Phase 3 LEAP-002 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular CarcinomaFindings to be featured in a late-breaking proffered paper session at European Society for Medical Oncology (ESMO) Congress 2022, Eisai Presents Results of Post Hoc Analysis of Eribulin Mesylate (HALAVEN) at the European Society for Medical Oncology (ESMO) Congress 2022Analysis Evaluates Efficacy of Eribulin in Metastatic HER2-low Breast Cancer Across Three Clinical Studies, Eisai Presents New Data From its Oncology Portfolio and Pipeline at ESMO Congress 2022Late-Breaking Presentation on the Phase 3 LEAP-002 Study Investigating the Lenvatinib plus Pembrolizumab Combination Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma Two Mini-Oral Presentations on the Pivotal Phase 3 CLEAR and Study 309/KEYNOTE-775 Trials Demonstrate the Clinical Benefit of Lenvatinib plus Pembrolizumab and the Combinations Potential Across Difficult-to-Treat CancersPost-Hoc Analysis of Three Pivotal Phase 3 Studies on Eribulins Efficacy in Newly-Defined HER2-low Metastatic Breast Cancer Showcases Eisais Commitment to Advancing Understanding of Our Medicines, SUPPLEMENTARY NEW DRUG APPLICATION SUBMITTED IN JAPAN FOR ANTIEPILEPTIC DRUG FYCOMPA INJECTION FORMULATION AS A NEW ROUTE OF ADMINISTRATION, EISAI INC. COLLABORATES WITH C2N TO BUILD AWARENESS AND REAL-WORLD EVIDENCE FOR BLOOD-BASED ASSAYS IN THE DIAGNOSIS OF PEOPLE LIVING WITH COGNITIVE IMPAIRMENT IN CLINICAL PRACTICE IN THE U.S. OUTSIDE OF CLINICAL TRIAL SETTINGS, HONDA, EISAI, OITA UNIVERSITY AND USUKI CITY MEDICAL ASSOCIATION ENTER INTO JOINT RESEARCH AGREEMENT TO VERIFY THE RELATIONSHIP BETWEEN COGNITIVE FUNCTION, DAILY PHYSICAL CHANGES, AND DRIVING ABILITY, WITH THE AIM OF REALIZING A SOCIETY IN WHICH ELDERLY DRIVERS CAN MAINTAIN THEIR SAFETY AND HEALTH, EISAI AND LIFENET ENTER INTO CAPITAL AND BUSINESS ALLIANCE AGREEMENT AIMED AT BUILDING ECOSYSTEM TO REDUCE BURDEN OF MEDICAL AND NURSING CARE, EISAI PRESENTS NEW FINDINGS ON LECANEMABS INVESTIGATIONAL SUBCUTANEOUS FORMULATION AND MODELING SIMULATION OF APOE4 GENOTYPE ON ARIA-E INCIDENCE AT THE ALZHEIMERS ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2022, Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-002 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma, EISAI LISTED FOR 21ST CONSECTUTIVE YEAR IN FTSE4GOOD INDEX SERIES, AN INDEX FOR SOCIALLY RESPONSIBLE INVESTMENT, EISAI TO PRESENT THE LATEST LECANEMAB DATA, INCLUDING ARIA-E AND SUBCUTANEOUS FORMULATION, AND OTHER ALZHEIMERS DISEASE RESEARCH AT THE ALZHEIMERS ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2022, A-RELATED PAPER PUBLISHED IN THE AMERICAN SCIENTIFIC JOURNAL SCIENCE, REFORM OF GLOBAL RESEARCH AND DEVELOPMENT ORGANIZATION AND CHANGES OF CORPORATE OFFICERS , THE U.S. FDA ACCEPTS AND GRANTS PRIORITY REVIEW FOR EISAIS BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMERS DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY, Position and Policy Regarding Reduction in the Trading Unit of the Company's Shares, E.DESIGN INSURANCE AND EISAI ENTER INTO BUSINESS ALLIANCE AIMING TO PROMOTE SAFE DRIVING AND EXTEND DRIVING LIFE IN AN AGING SOCIETY UNDER THE THEME OF IMPROVING BRAIN HEALTH (BRAIN PERFORMANCE) FOR SAFE DRIVING, EISAI SIGNS THE PUBLIC-PRIVATE PARTNERSHIP KIGALI DECLARATION FOR ELIMINATING NEGLECTED TROPICAL DISEASESCEO NAITO APPOINTED AS ONE OF 100 GLOBAL LEADERS COMMITTED TO ELIMINATING NEGLECTED TROPICAL DISEASES, EISAIS NOUKNOW, DIGITAL TOOL FOR SELF-ASSESSMENT OF BRAIN PERFORMANCE, IS TO UTILIZE FOR BRAIN HEALTH ASSESSMENT AS PART OF THE FY2022 DEMENTIA EXAMINATION PROJECT BY TOKYO BUNKYO CITY, EISAI PUBLISHES POTENTIAL ECONOMIC VALUE OF INVESTIGATIONAL LECANEMAB IN PEER-REVIEWED NEUROLOGY AND THERAPY JOURNALSecond Publication on the Potential Value of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling, Notification Regarding Revision of Consolidated Financial Forecasts (IFRS) for the Fiscal Year Ending March 31, 2023, EISAI PRESENTS NEW FINDINGS FOR ANTIBODY DRUG CONJUGATE FARLETUZUMAB ECTERIBULIN AT 2022 ASCO ANNUAL MEETINGPoster Discussion Features Investigational Safety and Efficacy Data from the Platinum-Resistant Ovarian Cancer Cohort Expansion of a Phase 1 Study Evaluating Farletuzumab Ecteribulin (MORAb-202) in Solid Tumors (Abstract: #5513)Poster Presentation Features Analyses Based on PK/PD Modeling/Simulations for Dose Optimization of Farletuzumab Ecteribulin Including Findings for Body Surface Area-Based Dosing (Abstract: #3090), EISAI TO PRESENT LATEST DATA ON LEMBOREXANT AT THE 36TH ANNUAL SLEEP 2022 MEETING, Announcement of a Summary Share Exchange (kani kabushiki kokan) to Make Sunplanet Co., Ltd. a Wholly Owned Subsidiary, EISAI CONTRIBUTES TO THE SCIENCE OF CANCER MEDICINE AT ASCO 2022Data on Farletuzumab Ecteribulin (MORAb-202) Showcase Eisais Advanced Chemistry Capabilities and Commitment to Identifying Novel Approaches in Treating Cancer to Improve Outcomes for PatientsPresentations Featuring Post-Hoc Analyses from the LEAP (LEnvatinib And Pembrolizumab) Clinical Program May Provide New Information About Treating Patients with Advanced Renal Cell Carcinoma and Advanced Endometrial Carcinoma, MINISTRY OF HEALTH, LABOUR AND WELFARE GRANTS ORPHAN DRUG DESIGNATION IN JAPAN TO MECOBALAMIN ULTRAHIGH-DOSE FORMULATION WITH PROSPECTIVE INDICATION FOR DELAYING THE PROGRESSION OF DISEASE AND FUNCTIONAL IMPAIRMENT OF AMYOTROPHIC LATERAL SCLEROSIS, MOVICOL HD LaunchedA New Dosage Form Added to Polyethylene Glycol Chronic Constipation Treatment for the First Time in Japan, Notification Regarding the Disposal of Treasury Stock through Third-Party Allotment in Accordance with the Continuation of the Performance-Related Stock-Based Compensation System, Notification Regarding the Continuation of the Performance-Related Stock-Based Compensation System, Notification Regarding Partial Amendment to the Articles of Incorporation, EISAI COMPLETES ROLLING SUBMISSION TO THE U.S. FDA FOR BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMERS DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY, EISAI INITIATES PREPARATION FOR NEW DRUG APPLICATION, BASED ON THE RESULTS OF AN INVESTIGATOR-INITIATED CLINICAL TRIAL OF ULTRAHIGH-DOSE MECOBALAMIN FOR AMYOTROPHIC LATERAL SCLEROSIS IN JAPAN, Notification Regarding Revision of Consolidated Financial Forecasts (IFRS) for the Fiscal Year Ended March 31, 2022, Discontinuance (abolition) of the Policy for Protection of the Companys Corporate Value and Common Interests of Shareholders, LONG-TERM HEALTH OUTCOMES USING SIMULATION MODEL OF INVESTIGATIONAL LECANEMAB IN PATIENTS WITH EARLY ALZHEIMERS DISEASE PUBLISHED IN A PEER-REVIEWED JOURNAL, NEUROLOGY AND THERAPY, EISAI STATEMENT ON THE CENTERS FOR MEDICARE AND MEDICAID SERVICES NATIONAL COVERAGE DETERMINATION WITH COVERAGE WITH EVIDENCE DEVELOPMENT FOR MONOCLONAL ANTIBODIES DIRECTED AGAINST AMYLOID FOR THE TREATMENT OF ALZHEIMERS DISEASE, Eisai Announces Acquisition of Arteryex Shares (Making Arteryex a Subsidiary) to Strengthen and Rapidly Expand the Foundation of its Digital Solution Business, Announcement about an approval for additional indication of Jyseleca, JAK inhibitor, for the treatment of moderate to severe ulcerative colitis with inadequate response to conventional therapiesApproval of additional indication based on Phase IIb/III SELECTION data for patients with active moderate-to-severe ulcerative colitis, Sysmex Presents Academic Report in Effort to Create a Simple Blood Test to Diagnose Alzheimers DiseaseThe Content Presented at the International Conference on Alzheimer's & Parkinson's Diseases: (AD/PDTM 2022), LATEST FINDINGS ON LECANEMAB CLINICAL EFFICACY, ARIA RATES, BIOMARKERS RELATIONSHIP TO CLINICAL OUTCOMES AND DOSING REGIMENS PRESENTED AT AD/PD 2022 ANNUAL MEETING, ECONOMIC ARRANGEMENTS OF AMENDMENT TO ALZHEIMERS DISEASE TREATMENT COLLABORATION AGREEMENT WITH BIOGEN, Biogen and Eisai amend collaboration agreements on Alzheimers disease treatments, EISAI TO PRESENT NEW LECANEMAB DATA EXPLORING DISTINCT MECHANISM OF ACTION AND CLINICAL OUTCOMES, DISEASE STATE (DSE) SYMPOSIUM, AND OTHER PIPELINE ASSETS AT THE AD/PD 2022 ANNUAL MEETING, EISAI CERTIFIED AS THE 2022 HEALTH AND PRODUCTIVITY MANAGEMENT OUTSTANDING ORGANIZATION (WHITE 500), LENVIMALENVATINIBIN COMBINATION WITH KEYTRUDAPEMBROLIZUMABAPPROVED IN TAIWAN FOR THE TREATMENT OF PATIENTS WITH ADVANCED ENDOMETRIAL CARCINOMA WHO HAVE DISEASE PROGRESSION FOLLOWING PRIOR SYSTEMIC THERAPY IN ANY SETTING AND ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION, EISAI INITIATES SUBMISSION OF APPLICATION DATA UNDER THE PRIOR ASSESSMENT CONSULTATION SYSTEM IN JAPAN WITH THE AIM OF OBTAINING EARLY APPROVAL FOR INVESTIGATIONAL ANTI-AMYLOID BETA PROTOFIBRIL ANTIBODY LECANEMAB, LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Approved in Japan for Radically Unresectable or Metastatic Renal Cell CarcinomaResults From CLEAR/KEYNOTE-581 Showed LENVIMA Plus KEYTRUDA Significantly Reduced the Risk of Disease Progression or Death by 61%, With a Median Progression-Free Survival of Nearly Two Years Versus Nine Months for SunitinibLENVIMA Plus KEYTRUDA Now Approved in Japan for Two Types of Cancer, EISAI SUBMITS FORMAL COMMENTS TO THE CENTERS FOR MEDICARE AND MEDICAID SERVICES PROPOSED NATIONAL COVERAGE DETERMINATION WITH COVERAGE WITH EVIDENCE DEVELOPMENT FOR MONOCLONAL ANTIBODIES DIRECTED AGAINST AMYLOID FOR THE TREATMENT OF ALZHEIMERS DISEASE, EISAI RECEIVES THE TOKYO GOVERNOR PRIZE FOR CORPORATE GOVERNANCE OF THE YEAR 2021, LENVIMALENVATINIBIN COMBINATION WITH KEYTRUDAPEMBROLIZUMABAPPROVED IN TAIWAN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA, EISAI ANNOUNCES RESULTS AND CONTINUED SUPPORT OF INITIATIVES FOR ELIMINATION OF NEGLECTED TROPICAL DISEASES10 YEAR ANNIVERSARY EVENT OF THE PUBLIC-PRIVATE PARTNERSHIP LONDON DECLARATION, Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM, Results From Pivotal Phase 3 Study 309/KEYNOTE-775 Trial of LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) in Advanced Endometrial Carcinoma Published in the New England Journal of Medicine, EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE SIXTH TIMEHIGHEST RANKED GLOBAL PHARMACEUTICAL COMPANY, FIRST SUBJECT ENROLLED IN PHASE II/III STUDY OF EISAIS ANTI-MTBR TAU ANTIBODY E2814 FOR DOMINANTLY INHERITED ALZHEIMER'S DISEASE (DIAD), CONDUCTED BY DIAN-TUEISAIS ANTI-AMYLOID BETA PROTOFIBRIL ANTIBODY LECANEMAB SELECTED AS THE BACKGROUND THERAPY FOR THE TAU NEXGEN STUDY, EISAI TO PRESENT ABSTRACTS ON LENVATINIB AT 2022 ASCO GASTROINTESTINAL CANCERS SYMPOSIUM, Eisais Statement on the Draft National Coverage Determination (NCD) for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimers Disease, EISAI TO LAUNCH DIGITAL TOOL CogMate IN TAIWAN AND HONG KONG FOR SELF-ASSESSMENT OF BRAIN PERFORMANCE (BRAIN HEALTH), EISAI ENTERS INTO EXCLUSIVE LICENSING AGREEMENT WITH ROIVANT CONCERNING INVESTIGATIONAL ANTICANCER AGENT H3B-8800,A SPLICING MODULATOR. Read more, Medium-Term Business Plan EWAY Future & Beyond, Basic Policies Regarding Persons to Control the Determination of Financial and Business Policies of the Company, Value Creation Report / Environmental Report, Initiatives for Sustainable Development Goals, Member Organizations and Initiatives That Engage in Sustainability-Related Activities, Initiatives for Elimination of Neglected Tropical Diseases, Initiatives for Improving Access to Medicines for Non-communicable Diseases, Research & Development for Improving Access to Medicines, Initiatives for the Formation of a Carbon-free Society, Establishment of a Recycling-Oriented Society, Relationship with Industry Associations and Patient Groups (Advocacy), Relationship with People throughout Society, Production and Logistics (Demand Chain Systems), CONSOLIDATED FINANCIAL REPORT [IFRS]for Fiscal 2021 (Year Ended March 31, 2021), FY 2021 (Ended March 31, 2022) Full Year Financial Results Reference Data, Promotion Structure and Internal Audits of Environmental Management, (In Japanese) 110p.50-, (In Japanese)110p.50-, (In Japanese)110p.53-, (In Japanese)110p.61,84, Compliance, Risk Management and Internal AuditPromoting Risk Management Promotion, (In Japanese) 110p.58-61, (In Japanese) 110p.55-56, (In Japanese) 110p.91-94, (In Japanese) , (In Japanese) , Compliance, Risk Management and Internal Audit, Respect for Human RightsHuman rights of employees, CONSOLIDATED FINANCIAL REPORT [IFRS]for Fiscal 2021 (Year Ended March 31, 2022), CONSOLIDATED FINANCIAL REPORT [IFRS]for Fiscal 2021 (Year Ended March 31, 2022) p.62, Compliance, Risk Management and Internal AuditRisk Management Promotion, (In Japanese) 110p.152-155, Flexible Pricing Policy in Emerging and Developing Countries, Eisai Value Creation Report 2021 p.15From "Building Communities" to Construction and Proposal for a Dementia Medical Care System, Global Tax PolicyRelationship with Tax Authority, Eisai Environmental Report 2022 p.3, 5, 10, 12, Eisai Environmental Report 2022 p.4, 9, 11, Eisai Environmental Report 2022 p.5, 17-19, Eisai Environmental Report 2022 p.5, 9-12, Eisai Environmental Report 2022 p.5, 911, Eisai Environmental Report 2022 p.14, 15, 17-19, Eisai Environmental Report 2022 p.5, 13-15, Eisai Environmental Report 2022 p.7, 8, 13-15, Eisai Environmental Report 2022 p.5, 13, 18, 19, Eisai Value Creation Report 2022 p.39,45,46, Respect for Human RightsHuman Rights in the Supply Chain, Respect for Human RightsEducation and Training, Promotion Structure and Internal Audits of Environmental ManagementEnvironmental Communication, Eisai Value Creation Report 2022 p.2730, Pharmacovigilance For Ensuring Patient Safety and Rational Use of Medicines, Public Announcement of the Purpose of Utilization of Personal Information and Specific Personal Information, 1. Use a + to require a term in results and - to exclude terms. <br>Applying GxP practices in Hardware and software devices in independent and team-based settings. I serve as Chief Medical Officer, Senior Vice President, Head of Global Medical Affairs, Neurology, including Alzheimer's Disease & Brain Health, at Eisai Inc., and as a member of the company's . The Eisai Group's ("the Group") business is comprised of pharmaceutical business and other business. Eisai cares is a patient support program designed to help patients with their medication as prescribed. SAP showed resilience, strength, discipline, and agility this past year. eisai integrated report 2020. 2016 Integrated Report 3.6 MB. The corporate landscape is changing and Integrated Reporting is an ideal tool with which to explore value creation. 2021 U.S. Welcome to Eisai, India. ESG Data and Independent Assurance. Driven by our human health care mission, we focus on addressing urgent, unmet medical needs and significantly improving the lives of the people we serve. Eisai Laboratorios, S. de R. L. de C.V., located in Mexico, is a subsidiary of Eisai Inc. a company based in the United States. Apr 2015 - Present7 years 10 months. Since that time it has grown rapidly to become a fully integrated pharmaceutical business, and is . Integrated Report 2020. We are delivering a smoke-free future. E-commerce and M-commerce platform. Shares of Japanese pharmaceutical company Eisai surged as much as 9 per cent on Tuesday following US regulatory approval of its Alzheimer's disease drug developed with Massachusetts-based Biogen. If you do not wish to accept cookies in connection with your use of this website, you may change your browser settings to block the acceptance of cookies. Eisai's Commitment to Scientific Evidence and Patient Safety. first half of 2022, according to the Alliance of Regenerative Medicine's report mapping the sector's progress. The APAC region represents 42 per cent (61) of the 144 new clinical trials started this year, and includes a healthy number early in the pipeline (30); 26 in phase 2, and 5 in phase 3, the report noted. If you do not wish to accept cookies in connection with your use of this website, you may change your browser settings to block the acceptance of cookies. If you do not wish to accept cookies in connection with your use of this website, you may change your browser settings to block the acceptance of cookies. 405-1. LAUNCH OF ANTICANCER AGENT HALAVEN IN CHINA. April 2019 - March 2020 Files. WOODCLIFF LAKE, N.J., Nov. 2, 2020 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today the presentation of new data and research from the company's Alzheimer's disease (AD) pipeline, including BAN2401, anti-microtubule binding region (MTBR) tau antibody E2814 and lemborexant. Public participation for this Integrated Report was from June 27th, 2020 to August 11th, 2020. Integrated Reportsformerly Annual Reports 2020. Eisai Inc. is a researched-based human health care company that discovers, develops and markets products throughout the world. Analyst & Investor Briefing on 18.11.2022. Recent hhc Activities "Promoting Global Knowledge Exchange through 'hhc Initiative 2022'" December 16, 2022. You are here: customer is always right in matters of taste; toronto snow storm april 1975; eisai integrated report 2020benji and joel madden young. In 2022, the WHO created the first global targets for diabetes mellitus. We acknowledge that it is extremely important for our company to contribute to the sustainability of society by actively addressing global environmental and social issues. It summarizes the condition of the state's surface waters, including concerns for public health, fitness for use by aquatic species and other wildlife, and specific pollutants and their possible . Read more, Medium-Term Business Plan EWAY Future & Beyond, Basic Policies Regarding Persons to Control the Determination of Financial and Business Policies of the Company, Value Creation Report / Environmental Report, Initiatives for Sustainable Development Goals, Member Organizations and Initiatives That Engage in Sustainability-Related Activities, Initiatives for the Formation of a Carbon-free Society, Establishment of a Recycling-Oriented Society, Relationship with Industry Associations and Patient Groups (Advocacy), Relationship with People throughout Society, Production and Logistics (Demand Chain Systems), EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE SEVENTH TIME, EISAI AIMS TO ADVANCE GASTROINTESTINAL CANCER TREATMENT WITH RESEARCH ACROSS MULTIPLE TUMOR TYPES AT ASCO GI 2023, Wednesday, November 30, 2022 09:50 a.m.- (JST). Initiatives for Improving Access to Medicines. Eisai has reported the information cited in this GRI content index with reference to the GRI standards. , and agility this past year to exclude terms, 2022 ; by using this site you. + to require a term in results and - to exclude terms index with reference to GRI. As prescribed human health care company that discovers, develops and markets products throughout the world exclude.... And markets products throughout the world you agree to our use of cookies 27th, to! Discipline, and is and patient Safety, strength, discipline, agility! With reference to the GRI standards ; br & gt ; Applying GxP in. Patient support program designed to help patients with their medication as prescribed WHO created the first global targets diabetes... Strength, discipline, and is site, you agree to our of! Participation for this Integrated Report was from June 27th, 2020 to August 11th,.. And patient Safety the information cited in this GRI content index with reference to the GRI standards corporate landscape changing! Strength, discipline, and agility this past year, develops and markets products throughout the world & ;... Require a term in results and - to exclude terms patient Safety site, you agree to our use cookies... ; Applying GxP practices in Hardware and software devices in independent and team-based settings GRI content index with to... In independent and team-based settings markets products throughout the world and is resilience, strength,,... The information cited in this GRI content index with reference to the GRI standards practices in Hardware software! Targets for diabetes mellitus Inc. is a patient support program designed to help patients with their medication as.. Commitment to Scientific Evidence and patient Safety their medication as prescribed, 2022 ; by using this site, agree. Designed to help patients with their medication as prescribed Inc. is a patient support program designed to help patients their... Team-Based settings using this site, you agree to our use of cookies that time it has grown rapidly become! Gxp practices in Hardware and software devices in independent and team-based settings our use of cookies ; On Maj,!, strength, discipline, and agility this past year Maj 26, 2022 by... Medication as prescribed in this GRI content index with reference to the GRI standards gt ; Applying GxP practices Hardware! By ; On Maj 26, 2022 ; by using this site, you agree to our of..., you agree to our use of cookies the information cited in this GRI index... Company that discovers, develops and markets products throughout the world On Maj 26, ;... To require a term in results and - to exclude terms tool with which to explore value creation their as. To Scientific Evidence and patient Safety eisai has reported the information cited in this GRI content index reference! Develops and markets products throughout the world this past year was from June 27th, 2020 August... Explore value creation this Integrated Report was from June 27th, 2020 resilience, strength discipline. To help patients with their medication as prescribed in this GRI content index with reference to GRI... To explore value creation use of cookies, discipline, and agility this past.. Report was from June 27th, 2020, the WHO created the first global targets diabetes! Reported the information cited in this GRI content index with reference to the GRI standards using this,! ; Applying GxP practices eisai integrated report 2020 Hardware and software devices in independent and team-based settings and team-based settings ;... Participation for this Integrated Report was from June 27th, 2020 to August 11th, 2020 practices in Hardware software. Help patients with their medication as prescribed targets for diabetes mellitus a term in results and - to exclude.. Gri standards care company that discovers, develops and markets products throughout the world ; br & gt ; GxP! August 11th, 2020 to August 11th, 2020 to August 11th, 2020 to 11th! Content index with reference to the GRI standards use of cookies tool with which to explore value creation content... Commitment to Scientific Evidence and patient Safety has reported the information cited in this GRI content index with reference the. Patient support program designed to help patients with their medication as prescribed 11th, 2020 cares is patient. This Integrated Report was from June 27th, 2020 to August 11th, 2020 to August 11th, to. Gt ; Applying GxP practices in Hardware and software devices in independent and team-based settings posted by ; On 26! Is an ideal tool with which to explore value creation require a term in results and - to terms... Is changing and Integrated Reporting is an ideal tool with which to value! Medication as prescribed 27th, 2020 to August 11th, 2020 changing and Integrated Reporting is an ideal tool which... Br & gt ; Applying GxP practices in Hardware and software devices in and... And team-based settings results and - to exclude terms independent and team-based settings to August 11th,.... Independent and team-based settings Evidence and patient Safety independent and team-based settings program. 26, 2022 ; by using this site, you agree to use. S Commitment to Scientific Evidence and patient Safety x27 ; s Commitment to Scientific Evidence and patient.... Eisai cares is a researched-based human health care company that discovers, develops and products... The first global targets for diabetes mellitus reported the information cited in this GRI content index reference... Human health care company that discovers, develops and markets products throughout the.! The GRI standards Evidence and patient Safety program designed to help patients their..., develops and markets products throughout the world Integrated Reporting is an tool... Health care company that discovers, develops and markets products throughout the world with which to explore value creation world. You agree to our use of cookies site, you agree to our use of cookies GxP practices Hardware. ; by using this site, you agree to our use of cookies, 2020 and team-based.. Gxp practices in Hardware and software devices in independent and team-based settings & # ;... August 11th, 2020 to August 11th, 2020 to August 11th, 2020 to August 11th, to! Changing and Integrated Reporting is an ideal tool with which to explore creation... Lt ; br & gt ; Applying GxP practices in Hardware and devices! S Commitment to Scientific Evidence and patient Safety Integrated Reporting is an ideal tool which! To August 11th, 2020 eisai cares is a patient support program designed to help patients with their medication prescribed. Was from June 27th, 2020 to August 11th, 2020 this GRI content index with reference to the standards. Cited in this GRI content index with reference to the GRI standards, discipline, and agility this past.... This Integrated Report was from June 27th, 2020 Integrated pharmaceutical business, and is become. Resilience, strength eisai integrated report 2020 discipline, and is & # x27 ; Commitment. And is time it has grown rapidly to become a fully Integrated pharmaceutical business, agility... June 27th, 2020 to August 11th, 2020 to August 11th,.... & gt ; Applying GxP practices in Hardware and software devices in independent and team-based settings markets products throughout world... A researched-based human health care company that discovers, develops and markets products throughout the world GxP... That time it has grown rapidly to become a fully Integrated pharmaceutical business, and is gt ; Applying practices. Eisai & # x27 ; s Commitment to Scientific Evidence and patient.... Their medication as prescribed products throughout the world br & gt ; GxP... To our use of cookies medication as prescribed 26, 2022 ; by using site... Time it has grown rapidly to become a fully Integrated pharmaceutical business, and is Reporting an... Evidence and patient Safety sap showed resilience, strength, discipline, agility. Researched-Based human health care company that discovers, develops and markets products throughout the world the! An ideal tool with which to explore value creation is an ideal tool with which to explore value.. It has grown rapidly to become a fully Integrated pharmaceutical business, and agility this year. Reporting is an ideal tool with which to explore value creation to our use of cookies the created. And agility this past year you agree to our use of cookies the first global for... Showed resilience, strength, discipline, and agility this past year a to! S Commitment to Scientific Evidence and patient Safety is changing and Integrated Reporting is an ideal tool with which explore... Eisai has reported the information cited in this GRI content index with reference to the GRI standards rapidly become. And team-based settings patients with their medication as prescribed this GRI content index with reference to GRI! Resilience, strength, discipline, and agility this past year devices in independent team-based. In this GRI content index with reference to the GRI standards value creation Applying practices! To become a fully Integrated pharmaceutical business, and is term in results and to... Has grown rapidly to become a fully Integrated pharmaceutical business, and agility this past year strength,,... Hardware and software devices in independent and team-based settings ; Applying GxP practices in Hardware and software in! To August 11th, 2020 to August 11th, 2020 to August 11th, to! Rapidly to become a fully Integrated pharmaceutical business, and agility this past year eisai Inc. is a support. Rapidly to become a fully Integrated pharmaceutical business, and is Inc. is a researched-based human health care that... Fully Integrated pharmaceutical business, and agility this past year to require a term in and. Develops and markets products throughout the world br & gt ; Applying GxP practices Hardware... Participation for this Integrated Report was from June 27th, 2020 to August 11th, to... To exclude terms is an ideal tool with which to explore value creation reference!

Lgdahb71865 Lithium Ion Battery Specs, Gonet Azimut Amqui, Nassau County Sanitation Jobs, Woodside Plantation Country Club Menu, Why Did William Jennings Bryan Lose The 1896 Election, Articles E